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Abstract
Background: Releasing drug molecules at the targeted location could increase the clinical outcome of a large
number of anti-tumor treatments which require low systemic damage and low side effects. Nano-carriers of drugs
show great potential for such task due to their capability of accumulating and releasing their payload specifically,
at the tumor site.
Results: FLT3 inhibitor - gold nanoparticle conjugates were fabricated to serve as vehicles for the delivery of anti-
tumor drugs. Lestaurtinib, midostaurin, sorafenib, and quizartinib were selected among the FLT3 inhibitor drugs that
are currently used in clinics for the treatment of acute myeloid leukemia. The drugs were loaded onto nanoparticle
surface using a conjugation strategy based on hydrophobic-hydrophobic interactions with the Pluronic co-polymer
used as nanoparticle surface coating. Optical absorption characterization of the particles in solution showed that FLT3
inhibitor-incorporated gold nanoparticles were uniformly distributed and chemically stable regardless of the drug
content. Drug loading study revealed a high drug content in the case of midostaurin drug which also showed
increased stability. Drug release test in simulated cancer cell conditions demonstrated more than 56 % release of the
entrapped drug, a result that correlates well with the superior cytotoxicity of the nano-conjugates comparatively with
the free drug.
Conclusions: This is a pioneering study regarding the efficient loading of gold nanoparticles with selected FLT3
inhibitors. In vitro cytotoxicity assessment shows that FLT3-incorporated gold nanoparticles are promising candidates as
vehicles for anti-tumor drugs and demonstrate superior therapeutic effect comparatively with the bare drugs.
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Background
Acute myeloid leukemia (AML) is one of the most com-
mon and deadly leukemias worldwide [1–3]. Its progno-
sis is poor, and a large number of AML cases will
relapse after initial healing. Clinicians currently use the
FMS-like tyrosine kinase 3 (FLT3) inhibitors such as les-
taurtinib, midostaurin, sorafenib, and quizartinib for
AML therapy [4–6]. But the administration of these
drugs systemically is associated with high toxicity and
severe side effects [7–9]. Therefore, it would be helpful
to refine the treatment accuracy by developing novel
markers or drugs that could improve the therapeutic
ratio and clinical outcome.
Nano-pharmacology is emerging as a new and highly
promising solution for the management of leukemias. By
designing specific delivery systems or nano-carriers,
higher drug concentrations can be transported to the ma-
lignant cell [10–12]. Specifically related to acute myeloid
leukemia, binding anti-FLT3 inhibitor drugs to nano-
carriers might offer a new and exciting approach to an
improved treatment. So far, no data has been published
related to the possibility to bind gold nanostructures or
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any other nanoparticles to tyrosine kinase inhibitors
(TKI), thus emphasizing the importance of the current
manuscript in the advancements of nano-pharmacology.
The only group that has so far attempted to use TKI
transported through nano-carriers in order to improve
the concept of personalized medicine was published
by Ljubimova recently [13]. This group has used poly-
malic acid-based nano-biopolymers to treat Her2/posi-
tive breast cancer. But, no others have so far succeeded to
improve the chemotherapy options using gold nanoparti-
cle (GNP) conjugation to TKI for hematological malignan-
cies, less alone AML. Directly related to the design and
development of anti-leukemic drugs, this report presents
a new class of GNP-FLT3 inhibitor nano-conjugates which
are promising candidates for the treatment of AML. These
nano-conjugates were fabricated to serve as vehicles for
the delivery of FLT3 inhibitor drugs lestaurtinib (LST),
midostaurin (MDS), sorafenib (SRF), and quizartinib
(QZR). The drugs were loaded onto the surface of nano-
particles using a conjugation strategy based on
hydrophobic-hydrophobic interactions with the Pluronic
co-polymer used as nanoparticle surface coating. Optical
absorption characterization of the nano-conjugates in so-
lution showed that FLT3 inhibitor-incorporated GNP were
uniformly distributed and chemically stable regardless of
the drug content. Dynamic light scattering (DLS) mea-
surements of the FLT3 inhibitor-loaded GNP revealed a
relatively uniform size and morphology of drug-loaded
particles. A drug loading study revealed an increased drug
content in the case of MDS drug which also showed
increased stability in phosphate buffer solution (PBS), in
time. Release test was conducted at characteristic pH and
glutathione level for cancer cells and demonstrated more
than 56 % release of the entrapped drug, a result that cor-
relates well with the measured superior cytotoxicity com-
paratively with the free drug or non-loaded nanoparticles.
This is a pioneering study regarding the efficient load-
ing of GNP with four different FLT3 inhibitors and their
characterization. In vitro cytotoxicity studies on two cell
lines (OCI-AML3 and THP1) demonstrate that FLT3-
loaded GNP are promising candidates as vehicles for
anti-tumor drugs and show superior therapeutic effect
than the freely administered drugs.
Methods
Materials
Hydrogen tetrachloroaurate (III) hydrate (HAuCl4
. 3H2O,
99.99 %), trisodium citrate (C6H5Na3O7), Pluronic F127
(powder, BioReagent, suitable for cell culture), lestaurtinib
hydrate (CEP-701, >98 %), midostaurin hydrate (>98 %),
and L-glutathione (cell culture tested, BioReagent, ≥98.0 %)
were purchased from Sigma-Aldrich. Quizartinib (AC220,
>99 %) was obtained from Seleckchem and Sorafenib
(>99 %) from Santa Cruz Biotechnologies.
Synthesis of Gold Nanoparticles
Citrate-capped spherical gold nanoparticles (GNP) were
synthesized by the aqueous reduction of HAuCl4 with
trisodium citrate according to the Turkevich-Frens
method [14]. Briefly, 100 ml of 1 mM HAuCl4
. 3H2O was
boiled, and a solution of 38.8 mM sodium citrate
(10 mL) was quickly added under vigorous stirring. Dur-
ing the boiling process, the solution changed its color
from yellow to intense burgundy-red. Then, the solution
was removed from the heat, and the stirring process
continued for another 10–15 min.
Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates
FLT3 inhibitors were dissolved in DMSO at a final con-
centration of 1 mg/ml. Forty microliters of these solu-
tions was added to 1 ml of GNP and incubated for a
specific time in the case of each drug. The incubation
time was determined in such a way to allow interaction
with GNP but to not induce aggregation (90 s for MDS,
60 s for LST, 30 s for SRF, and QZR was incubated to-
gether with Pluronic). Then, to capture the hydrophobic
molecules onto the surface of GNP and to stabilize the
obtained conjugates, Pluronic F127 was added to the
colloidal solution at a final concentration of 0.3 mM.
After 1 h incubation, the formed nano-conjugates were
purified from any unbound drug and polymer by centri-
fugation at 12,000 rpm for 20 min and resuspended in
ultrapure water for further measurements or in PBS for
stability tests and in vitro assays.
Loading Efficiency of FLT3 Inhibitors onto GNP
The amount of drugs loaded to GNP-Pl was calculated
by measuring the drug content of the supernatant after
purification of the particles by centrifugation. The load-
ing efficiency was then calculated using the following
formula:
%Loading efficiency ¼ Tdrug−Sdrug
Tdrug
 100
where Tdrug is the total amount of drug added and Sdrug
represents the amount of drug in supernatant. Drug
loading was calculated by estimating the free drug con-
tent of the supernatant remained after centrifugation of
the samples. The free drug concentrations in the super-
natant were determined from the calibration curve based
on Beer-Lambert law by linear interpolation of the read-
ings of supernatant absorbances.
GSH-Mediated Release of MDS
To investigate MDS release from gold nanoparticles,
150 μl of GNP-MDS-Pl dispersed in PBS was mixed
with 350 μl acetate buffer at pH 4.6 containing 10 mM
glutathione, and the mixture was maintained at constant
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37 °C for 24 h. For control measurements, the same
amount of nanoparticles was dispersed in PBS and kept
in the dark at 4 °C. At different intervals of time (0, 6,
and 24 h), both control and GSH mixtures were centri-
fuged, and the amount of MDS released into the super-
natant was calculated based on UV-Vis absorption
measurements.
Cell Culture Protocols
All cells were grown at 37 °C in a humidified atmosphere
of 95 % air and 5 % carbon dioxide (CO2). Cell passage
and culture were carried out as previously described [15,
16]. OCI-AML3 cell line was cultured in 80 % alpha-
MEM+ 20 % fetal bovine serum (FBS) (both from Sigma-
Aldrich), the cells being initially isolated from the periph-
eral blood of a 57-year-old man with acute myeloid
leukemia (AML FAB M4) at diagnosis in 1987. Cells carry
an NPM1 gene mutation (type A) and the DNMT3A
R882C mutation [17]. This cell line was kindly gifted by
Professor George Calin, MD, PhD (Department of Experi-
mental Therapeutics, The University of Texas MD Ander-
son Cancer Center, Houston, TX, USA). THP1 cells were
cultured using ATCC-formulated RPMI-1640 Medium
(ATCC, USA), being isolated from an acute monocytic
leukemia Japanese patient in 1980 [18]. The cell line was
kindly gifted by Associate Professor Mihnea Zdrenghea,
MD, PhD (Department of Hematology, Iuliu Hatieganu
University of Medicine and Pharmacy/Ion Chiricuta On-
cology Institute, Cluj Napoca, Romania).
Cell Counting
1.5 × 103 cells were plated in 24-well plates (day 0), treated
with the various drug combinations after 24 h, and counted
at days 1, 2, 4, 7, 10, and 14 by using both a hemocytometer
and a Leica S80 inverted phase contrast microscope, as well
as the Countess Automated Cell Counter (Invitrogen).
MTT Assay
Cell survival was assessed using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. Cells in monolayer culture were cultivated at sub-
confluence before being washed twice with PBS. Cells
were then resuspended in culture medium with FBS,
counted, and plated in 100 μl media at 15 × 103 cells/
well in 96-well microliter plates. After 24 h, the cells
were washed and treated with drugs/nanoparticles. The
final drug concentrations used for the in vitro assays
were established after the determination of the IC50
after extensive pilot projects (data not shown in this
paper) have been completed and having established the
best concentrations of drugs that should be used. The
cell culture medium was changed every 3 days with fresh
medium. Every time we changed the medium with a
fresh one, we centrifuged the cells and re-plated them in
different cell culture flasks. After the re-plating, we
added freshly made culture media, supplemented with
the investigated drugs and nanoparticles at the same
concentration as in the initial plating.
FLT3 drug-loaded GNP were compared with the cor-
responding conventional TKI at identical concentrations.
Absorbance of the MTT was measured at 492 nm using
a BioTek Synergy.
Statistical Analysis
The statistical analysis was performed using R (R Devel-
opment core team, USA) and GraphPad Prism 5.0
(GraphPad Software INC, CA, USA). The obtained data
was first examined for normality of distribution using
the Shapiro-Wilk test. The distribution of all the ob-
tained data was Gaussian, thus it was analyzed using a
parametric test (two-way ANOVA with Tukey’s post-
test). The differences were considered significant when
p < 0.05.
Equipment
Absorption spectra were recorded using a Jasco V-670
UV-Vis-NIR spectrometer with a slit width of 2 and
1 nm spectral resolution. Particle size distribution and
zeta potential were measured by a Zetasizer NanoZS90
instrument (Malvern Instruments). Analysis was per-
formed at a scattering angle of 90° and temperature of
25 °C. Dark field images of OCI-AML3 and THP1 cells
incubated with GNP-MDS-Pl were acquired using an
inverted Zeiss Axio Observer Z1 microscope. To capture
the cells, a few microliters of cell suspension were
dropped onto an Ibidi μ-Dish and enclosed with a cover
slip. A 100-W halogen lamp was used for illumination
which was focused on the sample using a high numerical
immersion condenser (NA = 1.4), and the scattered light
was collected by an LD Plan-Neofluar ×20 objective
(NA = 0.4, Zeiss).
Results and Discussion
Synthesis and Characterization of FLT3 Inhibitor - Gold
Nanoparticle conjugates
The strategy employed for conjugating FLT3 inhibitors
onto GNP implies the using of Pluronic F127 block co-
polymer as overall coating surface. Pluronic is an amphi-
philic polymer composed of hydrophobic poly(propylene
oxide) chains at the core and hydrophilic poly(ethylene
oxide) chains at the ends arranged in a A-B-A structure
(Fig. 1). Due to its amphiphilic nature and temperature-
dependent micellization characteristics, Pluronic can be
exploited for water-solubilization of hydrophobic
compounds and as drug carriers in delivery applica-
tions [19, 20]. Grafting a polymeric coating onto GNP
surface has the role of mediating the binding of drug
molecules and, equally important, to provide stability
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of the particles in biological media. By interfacing nano-
particles with the polymer above, we aimed to find the op-
timal type of nano-platform which provides the maximum
loading efficiency of the drug molecules onto GNP and
the highest stability in biologically relevant media.
The conjugation strategy relies on the direct attach-
ment of FLT3 drugs onto the surface of GNP
followed by their subsequent encapsulation in Pluro-
nic as schematized in Fig. 1.
GNP present a strong absorption band in the visible
region originating from the collective oscillation of free
electrons under light excitation, known as localized sur-
face plasmon resonance (LSPR). The intensity and wave-
length of the LSPR band depends on a variety of factors
which modify the electron charge density on the particle
surface, such as particle size and shape, structure, com-
position, and the dielectric constant of the surrounding
medium [21, 22]. Due to the high sensitivity of the LSPR
to the local refractive index of the environment sur-
rounding GNP surface, the loading of the drugs onto
nanoparticle surface can be efficiently monitored.
Therefore, we recorded the LSPR spectra of GNP in
water before and after interaction with the FLT3 in-
hibitor drugs (MDS, SRF, LST, and QZR) and encap-
sulation in Pluronic (Fig. 2). UV-Vis absorption
spectra of free drugs (in solution) were also recorded,
for reference. In all the cases, the addition of the
drug molecules to the solutions of nanoparticles in-
duced a red-shift of their LSPR maximum, a result
which can be considered as a first proof of
Fig. 1 Schematization of gold nanoparticle loading with midostaurin drug and stabilization with Pluronic
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nanoparticle loading. The spectral positions of the ab-
sorption maxima are also summarized in Table 1. The
differences in the magnitude of the LSPR shift (from
a value of 3 nm in the case of QZR to 9 nm in the
case of MDS) can be ascribed to the variation of the
refractive index in the vicinity of GNP as a conse-
quence of the different molecular species and the
amount of drug loaded. Besides the plasmonic bands
in the visible region, each spectrum of FLT3 drug-
GNP nano-conjugate presents spectral features also in
the UV domain, which originate from the electronic
absorption of the encapsulated FLT3 inhibitor molecules
(Fig. 2). In our opinion, a N-Au bonding between drugs
and nanoparticles is expected. For instance, MDS can bind
through its oxindole group which was found to attach to
gold nanoparticles [23, 24]. In the presence of Pluronic,
the hydrophobic PPO blocks of Pluronic encaged the
hydrophobic drug-nanoparticle conjugates while the
hydrophilic PEO chains are extended through the
aqueous phase ascertaining the solubility of nanopar-
ticles in water.
For each set of GNP-FLT3 inhibitor nano-conjugate,
the loading efficiency was calculated based on the UV-
Vis measurements as described in the experimental sec-
tion (Table 1). The most efficient drug loading was
found to be 80 % in the case of MDS, while conjugation
with the other three drugs determined relatively low
loading values (5–10 %). It is noteworthy that the shape
of the LSPR band remained unaffected in all of the four
cases, which indicates that the particles remained indi-
vidual in suspension and the conjugation with the drugs
did not cause any aggregation.
Fig. 2 UV-Vis extinction spectra measured in water of FLT3-inhibitor conjugated GNP-Pl (a), control GNP-Pl (b), and absorption spectra of
FLT3-inhibitors (c). (d) A-MDS, B-SRF, C-LST, D-QZR. Corresponding chemical structures of the investigated drugs are illustrated in the
upper side of the figures
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To further ascertain the formation of FLT3 drug-
GNP conjugates and get supplementary information
regarding the conjugation, DLS and zeta potential
measurements were performed. These techniques,
which provide information about hydrodynamic diam-
eter of the nanoparticles in colloidal solutions and
their surface charge in suspension, are ideal methods
to assess the loading of drugs [25]. It is worth to
mention that the diameters measured by DLS give
fairly higher values as measured by transmission elec-
tron microscopy (TEM), since it includes also the sur-
face coating of nanoparticles. For instance, bare GNP
having a physical diameter of ~12 nm measured by
TEM give a hydrodynamic diameter of 17 nm by
DLS. After encapsulation in Pluronic, the hydro-
dynamic diameter of GNP increases to 30 nm. Com-
pared to the drug-free nanoparticles (GNP-Pl), the
obtained nano-conjugates have significantly higher
hydrodynamic diameters (Table 1), which cannot be solely
attributed to the amount of drug loaded. It is known that
Pluronic co-polymers adsorb in different organizations
onto surfaces with different hydrophobicity [26]. When
adsorbing onto a hydrophobic surface in aqueous solution,
Pluronic has a “brush”-like organization with the hydro-
phobic PPO block grafted to the surface while the hydro-
philic PEO chains extend into the aqueous phase and
cover the surface with a PEO layer. On the contrary, for a
hydrophilic surface, Pluronic tends to attach to the surface
more loosely by the two PEO segments and form a less
“pancake” structure [27]. As citrate-capped gold nanopar-
ticles own a hydrophilic surface, we can assume such pan-
cake organization of Pluronic when stabilized without
drug loading. On the other hand, after association with
the hydrophobic drugs, the surface of nanoparticles be-
came more or less hydrophobic depending on the surface
coverage by drugs; therefore, a brush-like adsorption is
more probable. Moreover, the amount of Pluronic
adsorbed on a hydrophilic surface is generally lower than
that on a hydrophobic surface. We can attribute the large
difference in hydrodynamic diameter obtained between
drug-loaded and drug-free GNP-Pl to the different
amount of Pluronic adsorbed and to the different
organization at the surface of nanoparticles in function of
their hydrophobicity. Compared in between the four
drugs, the highest increase was observed for the GNP-
MDS-Pl conjugate which, in the one hand, is in very good
concordance with both the high loading efficiency and the
largest LSPR red-shift observed in the optical spectrum.
On the other hand, owing to the high concentration of
MDS loaded, we can assume that this type of particles
have the most hydrophobic surface after conjugation. We
do not exclude a combined polymer organization in case
of nanoparticles with lower drug content.
Moreover, the surface charge of the nanoparticles also
modifies as consequence of the interaction with the
FLT3 inhibitors and Pluronic (Table 1).
As the stability of the particles is a critical issue for
any use in biological media, the evolution of the ex-
tinction spectra of the prepared nano-conjugates were
monitored over time in PBS (Additional file 1: Figure
SF1). GNP-MDS-Pl proved to be very stable after
1 week storage in PBS, without any modification of
the plasmonic band. Contrarily, in the case of GNP-
SRF-Pl, the appearance of a second plasmonic max-
imum at longer wavelengths (~640 nm) indicates the
aggregation/agglomeration of the nanoparticles, most
probably organization in chain-like structures [28].
Such kind of chain formation was also observed in
the case of GNP conjugation with MDS if no Pluro-
nic was added to stabilize the nano-conjugates. Be-
cause of the hydrophobicity of these drug molecules,
in lack of a surface coating which can provide disper-
sability in hydrophilic medium or in case of insuffi-
cient surface coverage, the conjugated GNP tend to
aggregate or self-assembly. A slight aggregation also
occurs in the case of GNP-LST-Pl and GNP-QZR-Pl
after 1 week storage in PBS, indicated by the broad-
ening of the plasmonic band of the nanoparticles.
However, they are very similar in their chemical
structure, due to the two OH groups (see chemical
structure in Fig. 2). LST is more hydrophilic than
MDS, which weakens considerably the interaction
with Pluronic, thus resulting insufficient stability. These
results sustain our presumption regarding the different
Table 1 Size of FLT3 inhibitor conjugated GNP measured by DLS and PdI, their zeta potential together with zeta deviation, LSPR
position, and calculated drug loading efficiency
Sample Zeta potential (mV) Zeta deviation (mV) Diameter (nm) Polydispersity index (PdI) LSPR position (nm) Loading efficiency (%)
GNP −44 ± 2 5 ± 1 17 ± 2 0.45 519 –
GNP-PL −25 ± 2 10 ± 1 30 ± 1 0.54 520 –
GNP-MDS-PL −20 ± 1 9.8 ± 1 58 ± 2 0.46 529 80
GNP-SRF-PL −17.5 ± 0 .5 7.8 ± 3 48 ± 1 0.52 526 10
GNP-QZR-PL −5 ± 0.7 4 ± 0.2 58 ± 2 0.53 523 8
GNP-LST-PL −10 ± 0.5 8.5 ± 0.3 44 ± 2 0.95 527 10
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types of adsorption of Pluronic onto the surface of nano-
particles depending on their hydrophobicity.
Drug Release Test
Since the most efficient FLT3 drug loading was found
for the GNP-MDS-Pl which were also the most stable
in physiological medium, in the following, we limited
our investigations to this type of nano-conjugates.
The release of the drug payload from nanoparticles
was investigated under simulated biological conditions
of cancer cells, i.e., at 37 °C at a typical intracellular
glutathione (GSH) level (10 mM) and pH 4.6. On the
one hand, this release strategy relies on the significant
difference in intracellular and extracellular GSH con-
centration (1-10 mM intracellular [29] and 2 μΜ in
red blood plasma [30]). GSH has been widely utilized
as an external trigger for drug releases, due to the
strong affinity of the thiol ligand to the gold surface,
able to counteract with other types of interactions at
molecular level and to take place in exchange reactions
that can result the dissociation of drug molecules from the
nanoparticles, which will consequently be released. As the
N–Au bond is relatively weak (6 kcal/mol) compared to
the S–Au bond (47 kcal/mol) [31], one can expect that
GSH can replace the more loosely bound drug molecules
at the surface of gold nanoparticles. Such results were also
obtained by Mira Kim et al., who demonstrated that the
anti-cancer drug topotecan adsorbed onto the gold nano-
particle surface through its nitrogen atoms was detached
via external glutathione both in vitro and in vivo [32]. On
the other hand, the acidic environment in endosomal and
lysosomal compartments (4.5 < pH< 5) of cancer cells [33]
can also trigger the release of drugs from pH responsive
polymers such as Pluronic [34, 35]. In Fig. 3, the release is
expressed in wt% of the total amount of MDS attached to
the nanoparticles calculated using an UV-Vis absorption
calibration curve. GNP-MDS-Pl subjected to simulated
biological conditions (10 mM GSH, pH 4.6, and
temperature of 37 °C) show a significant drug release after
6 h of incubation (33 %), which increased up to 56 %
release of the total drug content in 24 h. For control sam-
ple, GNP-MDS-Pl in PBS kept at 4 °C, only a release of
10 % can be observed. UV-Vis absorption spectra of the su-
pernatants and the nanoparticles after each centrifugation
step (0, 6, and 24 h) are shown in Additional file 1: Figure
SF2 and SF3. After releasing the drug, the plasmonic band
of nano-conjugates suffered a significant broadening which
can be attributed to aggregated or interconnected nanopar-
ticles as a consequence of elimination of the stabilizing
Pluronic layer. The decrease of the absorption band of
MDS at 295 nm corroborates well the amount of drug
released and eliminated by the supernatant.
Dark Field Imaging of MDS-Gold Nanoparticle Conjugates
Inside Cells
The nanoparticle internalization by cells was analyzed by
dark field microscopy. Figure 4 presents the dark field
image of OCI-AML3 cells (A) and THP-1 (B) after 24 h in-
cubation with GNP-MDS-Pl. The nanoparticles can be
clearly visualized inside cells as diffraction-limited sparkling
(bright orange to reddish) dots due to the effective light
scattering at their SPR. GNP are usually uptaken by cells
via the endocytotic mechanism and accumulated in lyso-
somes [36]. Zoomed images from the inset of Fig. 4a, b
reveal an extranuclear localization of our nanoparticles in-
side both cell lines, the nucleus being clearly delimited as a
dark region. The variation in color of the nanoparticles is
related to various degrees of agglomeration of the nanopar-
ticles inside cellular vesicles. No similar scattering pattern
can be observed in the control sample, without nanoparti-
cles, which exhibit light scattering by cellular structures of
various optical densities (Fig. 4b, d).
In Vitro Evaluation of MDS-Gold Nanoparticle Conjugates
Current clinical data used MDS in combination with other
anti-cancer drugs such as 5-azacytidine [37], but this is ac-
companied by further toxicity and a decreased quality of
life for the leukemia patient [38]. Chemotherapy-refractory
or relapsed AML patients have a dismal prognosis, and
most of the times they do not reach the curative stem cell
transplantation. Thus, we must use drugs that have
already been developed and further enhance their ef-
fect through a more increased cancer cell penetration
and a decreased efflux of the drug. The newly synthe-
sized nanostructures were evaluated in vitro in order
to assess their potential efficacy in AML chemother-
apy. The leukemia cell proliferation was evaluated
using both standard cell counting, as well as the
spectrophotometer-based assay MTT. Figure 5a and b
Fig. 3 GSH and pH-mediated drug release by GNP-MDS-Pl
Simon et al. Nanoscale Research Letters  (2015) 10:466 Page 7 of 10
shows the survival curves for both OCI-AML3 cell
line and THP1 cell line, respectively. We can clearly
see that the TKI have a direct anti-leukemia effect,
further enhanced by the newly described drug, after
being loaded to GNP. We have chosen to enhance
the effect of MDS, as the drug alone has yet to reach
its expectations, as also confirmed by the clinical data
[39, 40].
The classic cell proliferation assay data was later on
confirmed using the MTT assay, as seen in Fig. 6a (for
the OCI-AML3 cell line) and 6b (for the THP1 cell line).
The data obtained using the proliferation assays are
Fig. 4 Dark field image of OCI-AML3 (a) and THP1 (b) cells in the presence of GNP-MDS-Pl nano-conjugates. Dark field image of OCI-AML3 (c)
and THP1 (d) cells (without nanoparticles). The insets show magnified images of cells; scale bars in insets represent 10 μm
Fig. 5 Survival curves for both OCI-AML3 cell line (a) and THP1 cell line (b)
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statistically significant, as shown in the Additional file 1:
Tables SF1 and SF2.
Conclusions
This paper presents the first demonstration of GNP
loading with selected FLT3 inhibitor drugs (midostaurin,
sorafenib, quizartinib, and lestaurtinib) and their assess-
ment as therapeutic agents against AML, inside living cells.
The efficient formation of FLT3-GNP bioconjugate com-
plex encapsulated in Pluronic was demonstrated by their
systematic characterization with various techniques,
including optical spectroscopy, DLS, and zeta potential in
solution. The loading efficiency was calculated for each of
the drug nano-conjugate and was found to be highest in
the case of MDS-loaded nanoparticles, which also proved
increased robustness and stability in time. Drug release
tests were conducted on GNP-MDS-Pl and showed that
more than half of the total drug amount was released under
simulated intracellular tumor cell conditions, a result which
corroborates with an increased therapeutic effect of the
nano-conjugates when compared with the free drug.
Additional file
Additional file 1: Figure SF1. Nanoparticle stability test by optical
spectroscopy. Figure SF2. Absorption spectra of supernatants from drug-
release assay. Figure SF3. Optical response of GNP-MDS-Pl after release.
Table SF1. Statistical analysis for the cell proliferation for OCI-AML3 cell line.
Table SF2. Statistical analysis for the cell proliferation for THP1cell line.
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